Anthropic präsentiert „Claude for Life Sciences“, eine KI-Plattform zur Optimierung der Pharmaforschung.
In Kürze
- Neue KI-Plattform beschleunigt Medikamentenentwicklung
- Direkte Verknüpfung mit Datenbanken und Labor-Tools
- Pharmakonzerne setzen bereits auf Claude
Anthropic’s New AI Platform: Claude for Life Sciences
Anthropic has launched a new AI platform called „Claude for Life Sciences,“ specifically designed for pharmaceutical research and laboratory process automation. The goal of this platform is to accelerate the development of new drugs and help researchers work more efficiently.
Scientific Connectors
A standout feature of Claude for Life Sciences is the so-called „scientific connectors.“ These enable a direct connection between Claude and important databases and lab tools. Researchers can thus utilize information from sources like PubMed and Benchling directly and contextually, without the need for tedious manual data transfer. This saves time and nerves—and who couldn’t use that?
The Claude Sonnet 4.5 Model
At the heart of the platform is the new Claude Sonnet 4.5 model. This model has the potential to exceed the performance of human experts in specific fields of biosciences. It assists in analyzing scientific literature and biological data, enabling faster validation of hypotheses. A true turbo for research!
Adoption by Leading Pharmaceutical Companies
Renowned pharmaceutical companies like Novo Nordisk and Sanofi are already using Claude in their research processes. They leverage the platform to analyze clinical study results and optimize laboratory work. Anthropic positions itself as a central partner in a data-intensive sector and actively contributes to shortening development cycles for new drugs.
Transforming Pharmaceutical Research
With this innovative platform, the way work is conducted in pharmaceutical research could fundamentally change.
Quellen
- Quelle: Anthropic
- Der ursprüngliche Artikel wurde hier veröffentlicht
- Dieser Artikel wurde im Podcast KI-Briefing-Daily behandelt. Die Folge kannst du hier anhören.
